<code id='9FCEF3872B'></code><style id='9FCEF3872B'></style>
    • <acronym id='9FCEF3872B'></acronym>
      <center id='9FCEF3872B'><center id='9FCEF3872B'><tfoot id='9FCEF3872B'></tfoot></center><abbr id='9FCEF3872B'><dir id='9FCEF3872B'><tfoot id='9FCEF3872B'></tfoot><noframes id='9FCEF3872B'>

    • <optgroup id='9FCEF3872B'><strike id='9FCEF3872B'><sup id='9FCEF3872B'></sup></strike><code id='9FCEF3872B'></code></optgroup>
        1. <b id='9FCEF3872B'><label id='9FCEF3872B'><select id='9FCEF3872B'><dt id='9FCEF3872B'><span id='9FCEF3872B'></span></dt></select></label></b><u id='9FCEF3872B'></u>
          <i id='9FCEF3872B'><strike id='9FCEF3872B'><tt id='9FCEF3872B'><pre id='9FCEF3872B'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:explore    Page View:73871
          Joaquin Duato -- health policy coverage from STAT
          Johnson & Johnson CEO Joaquin Duato MICHAEL BUHOLZER/AFP via Getty Images

          WASHINGTON — Merck CEO Robert Davis and Johnson & Johnson CEO Joaquin Duato have agreed to voluntarily testify before the Senate health committee, avoiding a threatened subpoena, the committee announced Friday.

          The decision by the executives came after a public pressure campaign by Sanders to get the two executives and Bristol Myers Squibb CEO Chris Boerner to testify about why prices for their drugs are higher in the United States than in other countries. Sanders had scheduled a vote to subpoena the Merck and Johnson & Johnson CEOs on Jan. 31, but canceled it on Friday.

          advertisement

          “​​The use of a subpoena was clearly a last resort and I’m delighted that these CEOs will be coming into our committee voluntarily,” Sanders said in a written statement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          23andMe had bad news about my health. I wish a person had delivered it
          23andMe had bad news about my health. I wish a person had delivered it

          ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

          read more
          Argenx readies a blockbuster opportunity with drug for autoimmune disease
          Argenx readies a blockbuster opportunity with drug for autoimmune disease

          MollyFerguson/STATHaveyouheardthenews?I’mlaunchingaweeklyemailnewsletterstartingonMarch28.It’scalled

          read more
          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more

          Health AI adoption puts security, privacy startups on investors' radar

          AdobeInvestorsarestartingtobackstartupsthatofferprivacyandsecurityservicestobolsterhealthAIproductsa